Cat. No.: HY-B0102

Fluoxetine

(Synonyms: LY-110140 free base)

46 Cited Publications

Avis client

Based on 46 publication(s) in Google Scholar

Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.09%
CAS No.: 54910-89-3
Formule: C₁₇H₁₈F₃NO
Masse moléculaire:309.33

Stockage:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fluoxetine Chemical Structure

CAS No.: 54910-89-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (46)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	13.1 μM Compound: 39	Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay	[PMID: 23121096]
HEK293	IC₅₀	16 nM Compound: fluoxetine	Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	4400 nM Compound: fluoxetine	Inhibition of DA transporter expressed in HEK293 cells Inhibition of DA transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	5200 nM Compound: fluoxetine	Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	16 nM Compound: fluoxetine	Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	4400 nM Compound: fluoxetine	Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	5200 nM Compound: fluoxetine	Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	47 nM Compound: 3	Inhibition of serotonin uptake at human SERT in human HEK293 cells Inhibition of serotonin uptake at human SERT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	2 μM Compound: 3	Inhibition of norepinephrine uptake at human NET in human HEK293 cells Inhibition of norepinephrine uptake at human NET in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	6 μM Compound: 3	Inhibition of dopamine uptake at human DAT in human HEK293 cells Inhibition of dopamine uptake at human DAT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	47 nM Compound: Fluoxetine	Inhibition of serotonin uptake at human SERT expressed in HEK cells Inhibition of serotonin uptake at human SERT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	2 μM Compound: Fluoxetine	Inhibition of norepinephrine uptake at human NET expressed in HEK cells Inhibition of norepinephrine uptake at human NET expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	6 μM Compound: Fluoxetine	Inhibition of dopamine uptake at human DAT expressed in HEK cells Inhibition of dopamine uptake at human DAT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	1020 nM Compound: Fluoxetine	Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	19500 nM Compound: Fluoxetine	Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	7 nM Compound: Fluoxetine	Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	1020 nM Compound: Fluoxetine	Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	19500 nM Compound: Fluoxetine	Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	7.3 nM Compound: Fluoxetine	Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	2.5 nM Compound: fluoxetine	Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells	[PMID: 20034793]
HEK293	IC₅₀	3.1 μM Compound: Prozac	Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells	[PMID: 20637635]
HEK293	IC₅₀	3.1 nM Compound: 2	Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells	[PMID: 20724153]
HEK293	IC₅₀	5.2 nM Compound: Fluoxetine	Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting	[PMID: 21093273]
HEK293	EC₅₀	2.7 nM Compound: 2	Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells	[PMID: 21927645]
HEK293	IC₅₀	8.6 nM Compound: fluoxetine	Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins	[PMID: 23403082]
HEK293	IC₅₀	7.2 nM Compound: Fluoxetine, Prozac	Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells	[PMID: 24012181]
HEK293	IC₅₀	150 nM Compound: Fluoxetine	Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	18400 nM Compound: Fluoxetine	Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	4410 nM Compound: Fluoxetine	Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	150 nM Compound: Fluoxetine	Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	18400 nM Compound: Fluoxetine	Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	4410 nM Compound: Fluoxetine	Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	14 μM Compound: 21	Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents	[PMID: 26588045]
HeLa	IC₅₀	10 μM Compound: 33; MMV001561	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay	[PMID: 30647879]
JAR	IC₅₀	32.4 nM Compound: fluoxetine	Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells	[PMID: 15239661]
JAR	IC₅₀	39.4 nM Compound: fluoxetine	Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells	[PMID: 16854086]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of 5HT uptake at human SERT expressed in human JAR cells Inhibition of 5HT uptake at human SERT expressed in human JAR cells	[PMID: 18557608]
JAR	IC₅₀	10 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
JAR	IC₅₀	39.4 nM Compound: fluoxetine	Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells	[PMID: 18834188]
JAR	IC₅₀	9.4 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18951020]
JAR	IC₅₀	10 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 19329313]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 19632110]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in JAR cells Inhibition of human SERT expressed in JAR cells	[PMID: 19713106]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells	[PMID: 19722525]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 20131864]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in human JAR cells Inhibition of human SERT expressed in human JAR cells	[PMID: 20378347]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of SERT-mediated serotonin uptake in human JAR cells Inhibition of SERT-mediated serotonin uptake in human JAR cells	[PMID: 20462211]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake	[PMID: 21916421]
K562	CC₅₀	25 μM Compound: 8	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
MCF7	IC₅₀	10 nM Compound: Fluoxetine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 32738968]
MDA-MB-231	IC₅₀	0.5 μM Compound: 41	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-436	IC₅₀	0.5 μM Compound: 41	Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDCK	IC₅₀	563 nM Compound: 1	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
RD	CC₅₀	11.9 μM Compound: Fluoxetine	Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method	[PMID: 30912944]
U-937	CC₅₀	33.3 μM Compound: 8	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
Ventricular myocyte	IC₅₀	2.82 μM Compound: Fluoxetine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell^[1]. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex^[2]. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus^[3]. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats^[1]. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group^[2]. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 54910-89-3
Appearance Liquid (Density: 1.159±0.06 g/cm³)
Masse moléculaire 309.33
Formule C₁₇H₁₈F₃NO
Color Colorless to light yellow
SMILES

FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F
Synonyms

LY-110140 free base
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (46)

All In Vivo ImagingIHCIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Nat Med

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. [Abstract]

2019 Sep;25(9):1428-1441. PMID: 31501614
Cell Metab

Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer. [Abstract]

2025 Dec 17:S1550-4131(25)00495-4. PMID: 41412121

Fluoxetine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Dec 17:S1550-4131(25)00495-4. [Abstract]

Ovarian cancer ID8 syngeneic model testing fluoxetine effect, Fluoxetine treatment (20 mg/kg over drinking water starting 7 days before first chemotherapy and continued until harvest), Cisplatin (5 mg/kg, twice/week, intraperitoneal injection in indicated time windows). The figure shows representative bioluminescence imaging results.

Fluoxetine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Dec 17:S1550-4131(25)00495-4. [Abstract]

Fluoxetine (20 mg/kg over drinking water starting 7 days before first chemotherapy and continued until harvest). Ovarian cancer PDX #1795 mouse model treated with PARPi (Olaparib) alone or with a combination of Fluoxetine.
Nat Commun

Targeting dopamine transporter for treating social transmission of depression-like behaviors in male mice. [Abstract]

2026 Jun 16. PMID: 42303982
Adv Sci (Weinh)

The GRK2/AP-1 Signaling Axis Mediates Vascular Endothelial Dysfunction and Atherosclerosis Induced by Oscillatory Low Shear Stress. [Abstract]

2025 Jun 10:e01981. PMID: 40492401
J Neuroinflammation

The involvement of NLRP3 inflammasome in CUMS-induced AD-like pathological changes and related cognitive decline in mice. [Abstract]

2023 May 10;20(1):112. PMID: 37165444
J Neuroinflammation

Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. [Abstract]

2017 Oct 30;14(1):210. PMID: 29084550
Phytomedicine

Sanhua essential oil exerts antidepressant effects in breast cancer-related depression by modulating metabolic pathways. [Abstract]

2026 Apr:153:157934. PMID: 41722126
Phytomedicine

WenDan Decoction activates neuronal autophagy in the hippocampus via the gut-brain axis to improve depressive-like behavior in HFD mice. [Abstract]

2025 Dec 8:150:157686. PMID: 41391369
J Transl Med

ML335 inhibits TWIK2 channel-mediated potassium efflux and attenuates mitochondrial damage in MSU crystal-induced inflammation. [Abstract]

2024 Aug 22;22(1):785. PMID: 39175013
Mol Med

The role of Dymeclin in chronic unpredictable mild stress-induced depression: maintaining the Golgi apparatus structure and regulating NLRP3 inflammasome activation. [Abstract]

2026 Jun 13. PMID: 42288765
Cell Rep

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. [Abstract]

2021 Nov 2;37(5):109957. PMID: 34731610
Cell Prolif

Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]

2021 Jan;54(1):e12953. PMID: 33211371
Brain Behav Immun

Depression-related chronic stress promotes ovarian cancer progression via metabolic dysfunction and IRF1-mediated immune suppression. [Abstract]

2026 Jan 26:134:106471. PMID: 41605304
Brain Behav Immun

Expression of Cntn1 is regulated by stress and associated with anxiety and depression phenotypes. [Abstract]

2021 Jul:95:142-153. PMID: 33737174

Fluoxetine purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2021 Jul:95:142-153. [Abstract]

Fluoxetine (20 mg/kg; ip). Representative images of DCX positive cells in the DG of hippocampus in different group.

Fluoxetine purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2021 Jul:95:142-153. [Abstract]

Fluoxetine (20 mg/kg; ip). Representative immunoblots of DCX and NeuN expression levels in different groups.
J Med Chem

Development of Novel Estradiol-Indole Hybrids Targeting SERT and ERβ as Potential Antidepressants. [Abstract]

2026 Jun 11;69(11):13618-13634. PMID: 42154662
Biochem Pharmacol

Melatonin protects HT-22 cells against palmitic acid-induced glucolipid metabolic dysfunction and cell injuries: Involved in the regulation of synaptic plasticity and circadian rhythms. [Abstract]

2023 Nov:217:115846. PMID: 37804870
Foods

Fermented Dendrobium officinale Ameliorates Sleep Deprivation-Induced Depressive-like Behaviors by Attenuating Neuroinflammation and Restoring 5-HT Synthesis via the Gut-Brain Axis. [Abstract]

2026 Jun 21;15(12):2237. PMID: 42354205
Eur J Pharmacol

Chronic co-treatment with geniposide and shanzhiside methyl ester elicits antidepressant effects via PACAP signaling in stressed male mice. [Abstract]

2026 Mar 28:1019:178713. PMID: 41794274
Eur J Pharmacol

Gypenoside XVII regulates apoptosis and fear extinction deficits mediated by post-traumatic stress disorder through the PERK/CHOP signaling pathway. [Abstract]

2025 Dec 15:1009:178391. PMID: 41276105
Eur J Pharmacol

SMIP004: A compound with antidepressant-like activities in mouse models. [Abstract]

2019 Jan 15:843:260-267. PMID: 30502341
Int Immunopharmacol

Fucosterol ameliorates depressive-like behaviours by suppressing microglial activation and neuroinflammation via inhibition the MAPK/ERK1/2 signaling pathway. [Abstract]

2025 May 10:158:114821. PMID: 40349406
Neurochem Int

Targeted stabilization of astrocytic Cx43 gap junctions reverses depression-like behaviors via dual restoration of syncytial networks and glutamatergic homeostasis. [Abstract]

2026 Jul-Aug:197:106168. PMID: 42102929
Gut Pathog

Lactobacillus reuteri DSM 17,938 ameliorates LPS-induced depression-like and anxiety-like behaviors by modulating gut microbiota and brain metabolic function. [Abstract]

2025 Aug 21;17(1):65. PMID: 40841920
Neuropharmacology

Hippocampal LASP1 ameliorates chronic stress-mediated behavioral responses in a mouse model of unpredictable chronic mild stress. [Abstract]

2021 Feb 15;184:108410. PMID: 33242526
Biomedicines

Two-Pore-Domain Potassium Channel TREK-1 Mediates Pulmonary Fibrosis through Macrophage M2 Polarization and by Direct Promotion of Fibroblast Differentiation. [Abstract]

2023 Apr 26;11(5):1279. PMID: 37238950
Prog Neuropsychopharmacol Biol Psychiatry

Harmine produces antidepressant-like effects via restoration of astrocytic functions. [Abstract]

2017 Jun 15;79(Pt B):258-267. PMID: 28625859

Fluoxetine purchased from MedChemExpress. Usage Cited in: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267. [Abstract]

Representative images showing the restoration effect of harmine on CUS-induced decrease in hippocampal DCX protein expressions. The Fluoxetine administration (20 mg/kg; ip) was used as a positive control, and all data were shown as mean ± SEM.
Virol J

KCNE4 is a crucial host factor for Orf virus infection by mediating viral entry. [Abstract]

2024 Aug 8;21(1):181. PMID: 39118175
Neurotox Res

Involvement of proBDNF in Monocytes/Macrophages with Gastrointestinal Disorders in Depressive Mice. [Abstract]

2020 Dec;38(4):887-899. PMID: 32588356
J Psychiatr Res

Acquisition and extinction of active avoidance compulsive-like behavior in mice. [Abstract]

2023 Oct 19:168:91-99. PMID: 39492237
World J Biol Psychiatry

SEP-363856 attenuates CUMS-induced depression-like behaviours and reverses hippocampal neuronal injuries. [Abstract]

2024 Nov 29:1-18. PMID: 39610275
Reprod Toxicol

Long-term Oral Fluoxetine Leads to Reduced Male Reproductive Function in Mice and Gradual Recovery After Discontinuation. [Abstract]

2025 Jan 16:108840. PMID: 39826770
Chem Biodivers

New 2,3-Methylenedioxy-naphthalene Derivatives With Neuroprotective Activity From the Roots of Ephedra sinica Stapf. [Abstract]

2025 Sep 24:e00918. PMID: 40991575
J Clin Psychopharmacol

Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. [Abstract]

2021 Sep-Oct;41(5):525-533. PMID: 34121064
Behav Brain Res

Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine?. [Abstract]

2017 Jan 15:317:62-70. PMID: 27633560
Fundam Clin Pharmacol

Tauroursodeoxycholic acid produces antidepressant-like effects in a chronic unpredictable stress model of depression via attenuation of neuroinflammation, oxido-nitrosative stress, and endoplasmic reticulum stress. [Abstract]

2018 Aug;32(4):363-377. PMID: 29578616
Biochem Biophys Res Commun

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]

2020 Feb 19;522(4):862-868. PMID: 31806372
Behav Pharmacol

Hesperidin produces antidepressant effects by activating AMPA receptor: enhancing synaptic proteins to promote hippocampal neuronal activities. [Abstract]

2025 Apr 1;36(2-3):127-136. PMID: 39611623
Behav Pharmacol

NSC689857, an inhibitor of Skp2, produces antidepressant-like effects in mice. [Abstract]

2024 Jun 1;35(4):227-238. PMID: 38651981
Behav Pharmacol

Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice. [Abstract]

2021 Feb 1;32(1):62-72. PMID: 33416256
bioRxiv

2026 May 29.
Research Square Preprint

2024 Dec 16.
Orebro University

2024.
Preprints

2023 Dec 27.
Research Square Preprint

2023 Jun 29.
Research Square Preprint

2023 Jun 16.
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (323.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2328 mL

16.1640 mL

32.3279 mL

5 mM

0.6466 mL

3.2328 mL

6.4656 mL

10 mM

0.3233 mL

1.6164 mL

3.2328 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (32.33 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[2]

Male Sprague-Dawley rats weighing 250-300 g are housed under a 12-hour light/12-hour dark cycle (lights on at 7:00 am, lights off at 7:00 pm) and at constant temperature (25°C) and humidity and allowed free access to food and water. For chronic drug treatments, rats are administered fluoxetine (5 mg/kg/day) or saline by intraperitoneal (IP) injection once daily and olanzapine or vehicle in the drinking water for 21 days (vehicle-treated control, fluoxetine, and olanzapine alone) plus the combination of fluoxetine and olanzapine. For combination treatment, olanzapine is chosen because fluoxetine is known to interfere with the metabolism of olanzapine and raise the blood levels by up to 4-6 times. Olanzapine is dissolved in hydrochloric acid (HCl), then adjusted back to pH 6 with 1 N sodium hydroxide to make the stock solution of 3 mg/mL concentration. The same amount of vehicle solution is added to the water for the control animals. Fluid intake is measured three times per week, and drinking bottles are replenwashed with fresh drug solution. There are no differences in fluid intake among the treatment groups. For subchronic treatment, drugs are administered exactly the same way but for a total period of 7 days.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (892 KB)
- English - EN (892 KB)
- Français - FR (892 KB)
- Deutsch - DE (892 KB)
- Norwegian - NO (892 KB)
- Español - ES (892 KB)
- Swedish - SV (892 KB)
- Italian - IT (892 KB)
- Korean - KR (892 KB)
- Portuguese - PT (892 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71 [Content Brief]

[2]. Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70. [Content Brief]

[3]. Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80. [Content Brief]

[4]. Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84. [Content Brief]

[5]. Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61 [Content Brief]

[6]. Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2328 mL	16.1640 mL	32.3279 mL	80.8198 mL
	5 mM	0.6466 mL	3.2328 mL	6.4656 mL	16.1640 mL
	10 mM	0.3233 mL	1.6164 mL	3.2328 mL	8.0820 mL
	15 mM	0.2155 mL	1.0776 mL	2.1552 mL	5.3880 mL
	20 mM	0.1616 mL	0.8082 mL	1.6164 mL	4.0410 mL
	25 mM	0.1293 mL	0.6466 mL	1.2931 mL	3.2328 mL
	30 mM	0.1078 mL	0.5388 mL	1.0776 mL	2.6940 mL
	40 mM	0.0808 mL	0.4041 mL	0.8082 mL	2.0205 mL
	50 mM	0.0647 mL	0.3233 mL	0.6466 mL	1.6164 mL
	60 mM	0.0539 mL	0.2694 mL	0.5388 mL	1.3470 mL
	80 mM	0.0404 mL	0.2020 mL	0.4041 mL	1.0102 mL
	100 mM	0.0323 mL	0.1616 mL	0.3233 mL	0.8082 mL

Keywords

Fluoxetine

46 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Fluoxetine

Publications Citing Use of MedChemExpress (MCE) Fluoxetine

Activité biologique

Chemical Information

Publications (46)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Fluoxetine Related Classifications

HY-B0102 Related Classifications